1 2 aim

Patient’s Sudden Death in Pfizer Gene Therapy Study

It is with great sadness we share the information we just received. A patient participating in Pfizer’s Phase 2 DAYLIGHT study for Duchenne muscular dystrophy has passed away suddenly. Pfizer issued the following letter to the community. The patient received the investigational gene therapy, fordadistrogene movaparvovec, in early 2023.


Read the official statement by Pfizer


We are following the company’s investigation closely regarding this tragic incident, and our hearts go out to the patient’s family and the community affected by this loss.